Jennifer Trendell received her BSc in Biological Science with Honours in Reproductive Biology and MSc by Research in Reproductive Biology from The University of Edinburgh in 2011 and 2012, respectively. She then worked as a Reproductive Laboratory Technologist and subsequently as an Oncology Clinical Trials Research Data Manager before undertaking a PhD at The University of Cambridge in 2015. Her PhD work was supervised by Prof. Nicholas Coleman and focused on the effects of Oncostatin-M receptor overexpression on mRNA and miRNA expression by cervical squamous cell carcinoma cells and their extracellular vesicles. She was awarded her PhD in 2020 and subsequently joined Prof. Andrew Tutt’s group at King’s College London as a postdoctoral Research Associate funded by Breast Cancer Now. Jennifer currently leads the patient derived xenograft (PDX) in vivo research programme within Prof. Tutt’s group. This research focuses on establishing PDX models from clinical samples obtained from breast cancer patients, with a focus on Triple Negative Breast Cancers (TNBCs), to aid understanding of mechanisms of therapy resistance and identify novel therapeutic targets.